{
    "clinical_study": {
        "@rank": "115893", 
        "arm_group": [
            {
                "arm_group_label": "LAYLA", 
                "arm_group_type": "Experimental", 
                "description": "Drug : LAYLA tablet/ bid"
            }, 
            {
                "arm_group_label": "JOINS", 
                "arm_group_type": "Active Comparator", 
                "description": "Drug : JOINS tablet/ tid"
            }
        ], 
        "brief_summary": {
            "textblock": "This is a randomized, double-blind study to compare the efficacy and safety of LAYLA tablet\n      and Joins tablet in the treatment of osteoarthritis of the knee."
        }, 
        "brief_title": "To Compare the Efficacy and Safety of LAYLA in Osteoarthritis Patients", 
        "completion_date": {
            "#text": "September 2013", 
            "@type": "Actual"
        }, 
        "condition": "Osteoarthritis of the Knee", 
        "condition_browse": {
            "mesh_term": [
                "Osteoarthritis", 
                "Osteoarthritis, Knee"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Patients \u226540 and \u2264 80years of age\n\n          -  Radiographic evidence of grade 2 or 3 osteoarthritis based on the Kellgren & Lawrene\n             radiographic entry criteria\n\n          -  Stable osteoarthritis during  3 months\n\n          -  Score of 100mm pain VAS \u2264 80mm at screening\n\n          -  Score of 100mm pain VAS \u2265 50mm at baseline\n\n          -  Written consent form voluntarily\n\n        Exclusion Criteria:\n\n          -  Disease of spine or other Lower limb joints that could affect to evaluate the\n             efficacy\n\n          -  History of surgery or arthroscopy of the study joint within 6 months\n\n          -  Trauma of study joint within 12 months\n\n          -  Medication of constantly(more than 1 week) corticosteroid by oral within 3 months\n\n          -  Medication of intra-articular injection within 3 months\n\n          -  Diagnosed with  psychical disorder, and taking medication\n\n          -  History of upper gastrointestinal ulceration within 6 months\n\n          -  History of upper gastrointestinal bleeding within 12 months\n\n          -  Serum creatinine, ALT, AST, total bilirubin over UNL X 2.0 at screening test\n\n          -  History of hypersensitivity to LAYLA, JOINS, or NSAIDs\n\n          -  Participation in another clinical trials within 4 weeks\n\n          -  Medication of constantly (more than 1 week) narcotic analgesics within 3 months\n\n          -  Not consent about using effectual contraception method during trial\n\n          -  Pregnant or lactating woman\n\n          -  Investigator's judgment"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "80 Years", 
            "minimum_age": "40 Years"
        }, 
        "enrollment": {
            "#text": "124", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "January 11, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01768468", 
            "org_study_id": "LAYLA-P4"
        }, 
        "intervention": [
            {
                "arm_group_label": "LAYLA", 
                "description": "1 tablet twice a day", 
                "intervention_name": "LAYLA tablet", 
                "intervention_type": "Drug", 
                "other_name": "LAYLA 405.4mg"
            }, 
            {
                "arm_group_label": "JOINS", 
                "description": "1 tablet at each time, 3 times a day", 
                "intervention_name": "JOINS tablet", 
                "intervention_type": "Drug", 
                "other_name": "JOINS 200mg"
            }
        ], 
        "is_fda_regulated": "No", 
        "keyword": [
            "LAYLA", 
            "Non-inferiority", 
            "100mm pain VAS"
        ], 
        "lastchanged_date": "October 11, 2013", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Daegu", 
                        "country": "Korea, Republic of"
                    }, 
                    "name": "Keimyug University Dongsan Medical Center"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Seoul", 
                        "country": "Korea, Republic of"
                    }, 
                    "name": "Hanyang University Guri Hospital"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Seoul", 
                        "country": "Korea, Republic of"
                    }, 
                    "name": "Samsung Medical Center"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Seoul", 
                        "country": "Korea, Republic of"
                    }, 
                    "name": "Korea University Anam Hospital"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Seoul", 
                        "country": "Korea, Republic of"
                    }, 
                    "name": "SMG-SNU Boramae Medical Center"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Suwon", 
                        "country": "Korea, Republic of"
                    }, 
                    "name": "Ajou University Hospital"
                }
            }
        ], 
        "location_countries": {
            "country": "Korea, Republic of"
        }, 
        "number_of_arms": "2", 
        "official_title": "Double Blinded, Randomized, Active Drug Comparative, Multi-center, Phase IV Clinical Study to Compare the Efficacy and Safety of LAYLA in Osteoarthritis Patients", 
        "overall_official": [
            {
                "affiliation": "Hanyang University", 
                "last_name": "Ye Soo Park", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "Samsung Medical Center", 
                "last_name": "Chul Won Ha", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "Ajou University School of Medicine", 
                "last_name": "Ye Yeon Won", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "SMG-SNU Boramae Medical Center", 
                "last_name": "Jae Hyup Lee", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "Keimyug University Dongsan Medical Center", 
                "last_name": "Byung Woo Min", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "Korea University Anam Hospital", 
                "last_name": "Seung Beom Han", 
                "role": "Principal Investigator"
            }
        ], 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "Korea: Institutional Review Board", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 4", 
        "primary_completion_date": {
            "#text": "June 2013", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "measure": "Change in 100mm Pain VAS", 
            "safety_issue": "No", 
            "time_frame": "baseline throgh week 8"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01768468"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Change from baseline in 100mm pain VAS", 
                "safety_issue": "No", 
                "time_frame": "12 weeks"
            }, 
            {
                "measure": "Change rate from baseline in 100mm Pain VAS", 
                "safety_issue": "No", 
                "time_frame": "8 weeks, 12 weeks"
            }, 
            {
                "measure": "Change from baseline in WOMAC", 
                "safety_issue": "No", 
                "time_frame": "8 weeks, 12 weeks"
            }, 
            {
                "measure": "Change from baseline in EQ-5D", 
                "safety_issue": "No", 
                "time_frame": "8 weeks, 12 weeks"
            }, 
            {
                "measure": "Change in the patient self-assessed & investigator-assessed overall symptom score", 
                "safety_issue": "No", 
                "time_frame": "8 weeks, 12 weeks"
            }, 
            {
                "measure": "Consumption of rescue medication", 
                "safety_issue": "No", 
                "time_frame": "4 times"
            }
        ], 
        "source": "PMG Pharm Co., Ltd", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "PMG Pharm Co., Ltd", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "October 2012", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "October 2013"
    }
}